BLOOMFIELD, N.J., March 28 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Susanna Rybak, Ph.D., Member of Alfacell’s Scientific Advisory Board, will present at the 2nd Fabisch-Symposium for Cancer Research and Molecular Cell Biology, to be held from March 30 through April 1, 2006 in Berlin, Germany.
The symposium focus is on targeted tumor therapies. Dr. Rybak’s invited presentation, entitled “RNase-based Targeted Therapeutics,” will feature work conducted in collaboration with Alfacell during her tenure at the National Cancer Institute (NCI) on a novel chemical conjugate coupling ONCONASE(R) (ranpirnase) with an anti-CD22 antibody. This molecule has been shown to clearly eradicate human non-Hodgkin’s lymphoma cells in murine models of cancer. Dr. Rybak has pioneered the use of RNase proteins as antibody- delivered payloads since the early 1990’s.
“ONCONASE / antibody chemical conjugates can be as potent in killing tumor cells as those using plant and bacterial toxins, but are far less toxic to mice than classical immunotoxins. Based on these preclinical studies, we can expect a wider therapeutic index in humans,” stated Dr. Rybak. “Several studies showed molecules targeting a wide range of cancer-associated antigens can successfully deliver ONCONASE. This increases the potency and specificity of ONCONASE for diverse types of tumors, both solid- and blood-borne.”
For more information about the symposium, please visit http://www.charite.de/fabisch/.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other diseases, using its ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell Corporation
CONTACT: Kuslima Shogen or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Investor/Media Relations, Dodi Handyof Elite Financial Communications, +1-407-585-1080, acel@efcg.net, forAlfacell Corporation
